Floatz Rating
B60/100
Confidence
Indicative
Sponsor
SWOG Cancer Research Network
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
53High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07383441CT.gov Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer | — | Recruiting | — | — | — |
NCT07469683CT.gov An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma | — | Recruiting | — | — | — |
NCT07227415CT.gov Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer | — | Recruiting | — | — | — |
NCT07123090CT.gov A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma | — | Recruiting | — | — | — |
NCT06860386CT.gov Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC | — | Suspended | — | — | — |
NCT06690697CT.gov Combination of Toripalimab and JS004 Therapy for ccRCC | — | Recruiting | — | — | — |
NCT05176288CT.gov Avelumab, Palbociclib and Axitinib in Advanced RCC | — | Withdrawn | — | — | — |
NCT06279403CT.gov Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT05363631CT.gov Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab | — | Active Not Recruiting | — | — | — |
NCT04995016CT.gov Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma | — | Unknown | — | — | — |
Show 9 more trialsShow fewer
NCT04958473CT.gov A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer | — | Unknown | — | — | — |
NCT04370509CT.gov Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery | — | Terminated | — | — | — |
NCT03438708CT.gov Prior Axitinib as a Determinant of Outcome of Renal Surgery | — | Active Not Recruiting | — | — | — |
NCT03092856CT.gov Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer | — | Active Not Recruiting | — | — | — |
NCT02667886CT.gov Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma | — | Completed | — | — | — |
NCT02700568CT.gov Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors | — | Completed | — | — | — |
NCT02535533CT.gov SLM + Axitinib for Clear Cell RCC | — | Completed | — | — | — |
NCT01693822CT.gov A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy | — | Completed | — | — | — |
NCT05941637CT.gov An Expanded Access Program to Axitinib is Available for Patients With Advanced Forms of Kidney Cancer (Ductal; Papillary; Chromophobic; Oncocytic) With Mutations in VHL, PBRM1 / BAP1, SETD2, VEGF) | — | No Longer Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Nonpapillary Renal Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Axitinib (this asset) | SWOG Cancer Research Network | P3 | B · 60 |
| Girentuximab | Massachusetts General Hospital | P3 | BB |
| Clostridium Butyricum Miyairi 588 | City of Hope Medical Center | P3 | BB |
| Pazopanib | Academic and Community Cancer Research United | P4 | BB |
| Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer | Regeneron Pharmaceuticals | P2 | BB |
| Cabozantinib | SWOG Cancer Research Network | P3 | BB |
| Nivolumab | Fred Hutchinson Cancer Center | P3 | BB |
| Cyclophosphamide | City of Hope Medical Center | P3 | B |
| Irinotecan | M.D. Anderson Cancer Center | P3 | B |
+42 more in the Nonpapillary Renal Cell Carcinoma cohort
Other indications for Axitinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Kidney Neoplasm | — | P3 | BB · 69 |
| Renal Cell Carcinoma | — | P4 | BB · 67 |
| Kidney Cancer | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- GirentuximabMassachusetts General HospitalBB
- Clostridium Butyricum Miyairi 588City of Hope Medical CenterBB
- PazopanibAcademic and Community Cancer Research UnitedBB
- Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, DimerRegeneron PharmaceuticalsBB
- CabozantinibSWOG Cancer Research NetworkBB
Citation
Floatz Terminal. Axitinib in Nonpapillary Renal Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/axitinib-nonpapillary-renal-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →